INBX vs REGN
INBX: Inhibrx Biosciences is a clinical-stage biotechnology company leveraging advanced protein engineering to develop targeted therapeutic candidates for complex diseases. REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases.
Side-by-side fundamentals
| Metric | INBX | REGN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $92.76 | $739.57 | |
| Market cap | $1.4B | $69.5B | |
| P/E as of 2026-10-08 | n/a | 18.28 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 6.61 | |
| Net margin FY2025, SEC XBRL | -10773.5% | +31.4% | REGN higher |
| Operating margin FY2025, SEC XBRL | -10386.5% | +24.9% | REGN higher |
| ROE FY2025, SEC XBRL | -1752.2% | +14.4% | REGN higher |
| ROA FY2025, SEC XBRL | -95.6% | +11.1% | REGN higher |
| Debt / equity as of 2026-09-02 | 12.58 | 0.09 | REGN lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +9.3% | |
| Revenue CAGR (3y) SEC XBRL | -15.0% | +5.6% | REGN higher |
| Dividend yield as of 2026-09-02 | n/a | +0.5% | |
| Beta as of 2026-09-02 | 1.28 | 0.61 | |
| 1-year return as of 2026-10-08 close | +176.0% | +31.2% | INBX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.